5 results about "Use insulin" patented technology

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor / PI3K / AKT / mTOR pathway, and / or use of diet that influences the subject's metabolic state.

This invention belongs to the field of fungal polysaccharide application technology, specifically relating to a method for preparing and applying polysaccharide from *Boletus globosum*. Crude polysaccharide was extracted from the fruiting body of *Boletus globosum* using hot water extraction, and purified using DEAE-52 cellulose column chromatography. Subsequently, by establishing an alcohol-induced liver injury model, it was found that NOP-1 significantly reduced ALT and AST levels, while simultaneously decreasing MDA content and increasing SOD activity and GSH levels, indicating that NOP-1 can inhibit lipid peroxidation, enhance the antioxidant defense capacity of hepatocytes, and maintain hepatocyte membrane integrity. A HepG2 cell IR model was constructed using a high-glucose, high-insulin combined induction method, determining the optimal dosage of NOP-1. ‑6 Treatment of HepG2 cells with mol / L insulin for 24 h successfully induced insulin resistance. Glucose consumption experiments in IR HepG2 cells demonstrated that NOP-1 significantly enhanced the glucose consumption capacity of insulin-resistant cells, exhibiting significant in vitro hypoglycemic activity.

The invention discloses application of insulin in regulation and control of LC-PUFA (liquid chromatography-polyunsaturated fatty acid) biosynthesis of eriocheir sinensis, and belongs to the technical field of bioengineering. The invention provides an application of insulin in preparation of a preparation for regulating and controlling eriocheir sinensis LC-PUFA biosynthesis, insulin is taken as an active component, and the content of LC-PUFA is regulated and controlled in a targeted manner by improving the PIK3Ralpha gene expression of eriocheir sinensis. The invention further provides application of the combination of the insulin and the PI3K agonist 740Y-P in preparation of a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis. The invention also provides a preparation for regulating and controlling the LC-PUFA biosynthesis of the eriocheir sinensis, which comprises an effective amount of insulin as an active component and also comprises a PI3K agonist 740Y-P. Experiments prove that the insulin regulates and controls the LC-PUFA biosynthesis of the eriocheir sinensis in a targeted manner through a PIK3 signal channel, and a general strategy is provided for nutrition regulation and control of crustaceans.